464 related articles for article (PubMed ID: 29495002)
21. The combination of NVP-BKM120 with trastuzumab or RAD001 synergistically inhibits the growth of breast cancer stem cells in vivo.
Yu F; Zhao J; Hu Y; Zhou Y; Guo R; Bai J; Zhang S; Zhang H; Zhang J
Oncol Rep; 2016 Jul; 36(1):356-64. PubMed ID: 27175939
[TBL] [Abstract][Full Text] [Related]
22. [Molecular mechanisms of resistance to phosphatidyl inositol 3-kinase inhibitors in triple-negative breast cancer cells].
Zhang WL; Ma WJ; Chen S; Wu XZ; Zhang HR; Zhang JH
Zhonghua Zhong Liu Za Zhi; 2016 Aug; 38(8):578-88. PubMed ID: 27531477
[TBL] [Abstract][Full Text] [Related]
23. BKM120 induces apoptosis and inhibits tumor growth in medulloblastoma.
Zhao P; Hall J; Durston M; Voydanoff A; VanSickle E; Kelly S; Nagulapally AB; Bond J; Saulnier Sholler G
PLoS One; 2017; 12(6):e0179948. PubMed ID: 28662162
[TBL] [Abstract][Full Text] [Related]
24. Inhibitor of pan class-I PI3K induces differentially apoptotic pathways in acute leukemia cells: Shedding new light on NVP-BKM120 mechanism of action.
Bashash D; Safaroghli-Azar A; Delshad M; Bayati S; Nooshinfar E; Ghaffari SH
Int J Biochem Cell Biol; 2016 Oct; 79():308-317. PubMed ID: 27599915
[TBL] [Abstract][Full Text] [Related]
25. Resveratrol potentiates the anti-tumor effects of rapamycin in papillary thyroid cancer: PI3K/AKT/mTOR pathway involved.
Bian P; Hu W; Liu C; Li L
Arch Biochem Biophys; 2020 Aug; 689():108461. PubMed ID: 32531316
[TBL] [Abstract][Full Text] [Related]
26. [NVP-BKM120 in combination with letrozole inhibit human breast cancer stem cells via PI3K/mTOR pathway].
Liu Y; Zhang XB; Liu JJ; Zhang S; Zhang J
Zhonghua Yi Xue Za Zhi; 2019 Apr; 99(14):1075-1080. PubMed ID: 30982255
[No Abstract] [Full Text] [Related]
27. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
Kanteti R; Riehm JJ; Dhanasingh I; Lennon FE; Mirzapoiazova T; Mambetsariev B; Kindler HL; Salgia R
Sci Rep; 2016 Sep; 6():32992. PubMed ID: 27623107
[TBL] [Abstract][Full Text] [Related]
28. Blockade efficacy of MEK/ERK-dependent autophagy enhances PI3K/Akt inhibitor NVP-BKM120's therapeutic effectiveness in lung cancer cells.
Ren H; Guo H; Thakur A; Zhang S; Wang T; Liang Y; Shi P; Gao L; Liu F; Feng J; Chen T; Yang T; Shang D; Liu JJ; Xu F; Chen M
Oncotarget; 2016 Oct; 7(41):67277-67287. PubMed ID: 27572309
[TBL] [Abstract][Full Text] [Related]
29. Chloroform extract from Sophora Tonkinensis Gagnep. inhibit proliferation, migration, invasion and promote apoptosis of nasopharyngeal carcinoma cells by silencing the PI3K/AKT/mTOR signaling pathway.
ShuoWang ; Song Z; Gong X; Ou C; Zhang W; Wang J; Yao C; Qin S; Yan B; Li Q; Wei K; Hou X; Zhou X; Miao J
J Ethnopharmacol; 2021 May; 271():113879. PubMed ID: 33524509
[TBL] [Abstract][Full Text] [Related]
30. Ropivacaine suppresses tumor biological characteristics of human hepatocellular carcinoma via inhibiting IGF-1R/PI3K/AKT/mTOR signaling axis.
Zhang R; Lian Y; Xie K; Cai Y; Pan Y; Zhu Y
Bioengineered; 2021 Dec; 12(2):9162-9173. PubMed ID: 34696683
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma.
Zang C; Eucker J; Liu H; Coordes A; Lenarz M; Possinger K; Scholz CW
Leuk Lymphoma; 2014 Feb; 55(2):425-34. PubMed ID: 23721513
[TBL] [Abstract][Full Text] [Related]
32. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.
Mueller A; Bachmann E; Linnig M; Khillimberger K; Schimanski CC; Galle PR; Moehler M
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1601-15. PubMed ID: 22543857
[TBL] [Abstract][Full Text] [Related]
33. NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.
Park E; Park J; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
Int J Oncol; 2012 Apr; 40(4):1259-66. PubMed ID: 22159814
[TBL] [Abstract][Full Text] [Related]
34. PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.
Zache N; Lambert JM; Wiman KG; Bykov VJ
Cell Oncol; 2008; 30(5):411-8. PubMed ID: 18791272
[TBL] [Abstract][Full Text] [Related]
35. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
[TBL] [Abstract][Full Text] [Related]
36. Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits.
Hao J; Fan W; Li Y; Tang R; Tian C; Yang Q; Zhu T; Diao C; Hu S; Chen M; Guo P; Long Q; Zhang C; Qin G; Yu W; Chen M; Li L; Qin L; Wang J; Zhang X; Ren Y; Zhou P; Zou L; Jiang K; Guo W; Deng W
J Exp Clin Cancer Res; 2019 Feb; 38(1):48. PubMed ID: 30717768
[TBL] [Abstract][Full Text] [Related]
37. Targeting the PI3K signaling pathway in KRAS mutant colon cancer.
Hong S; Kim S; Kim HY; Kang M; Jang HH; Lee WS
Cancer Med; 2016 Feb; 5(2):248-55. PubMed ID: 26715098
[TBL] [Abstract][Full Text] [Related]
38. AIM2 inhibits the proliferation, invasion and migration, and promotes the apoptosis of osteosarcoma cells by inactivating the PI3K/AKT/mTOR signaling pathway.
Zheng J; Liu C; Shi J; Wen K; Wang X
Mol Med Rep; 2022 Feb; 25(2):. PubMed ID: 34913077
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas.
Anderson JL; Park A; Akiyama R; Tap WD; Denny CT; Federman N
PLoS One; 2015; 10(9):e0133610. PubMed ID: 26402468
[TBL] [Abstract][Full Text] [Related]
40. Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.
Gallagher EJ; Fierz Y; Vijayakumar A; Haddad N; Yakar S; LeRoith D
Oncogene; 2012 Jul; 31(27):3213-22. PubMed ID: 22037215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
